Physician profile
Irina Kumar
NPI 1851414247
$6,524.14
in general payments reported to CMS, 2019-2025
30 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,453 · 2022: $2,603 · 2023: $540 · 2024: $732 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,671.49 | 2021-2023 | |
| Novo Nordisk INC | $885.04 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $544.17 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $352.53 | 2021-2025 | |
| Dexcom, INC. | $349.31 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $344.98 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.62 | 2021-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $336.32 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $269.01 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $232.38 | 2021-2022 | |
| Glaxosmithkline, LLC. | $182.40 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Shield Therapeutics INC | $157.26 | 2023-2025 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $153.67 | 2021-2022 | |
| Amgen INC. | $144.44 | 2022-2025 | Otezla, Repatha, Prolia |
| Merck Sharp & Dohme LLC | $100.66 | 2021-2025 | Vaxneuvance, Capvaxive |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $84.81 | 2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $47.41 | 2021 | |
| Horizon Therapeutics Plc | $45.71 | 2021-2022 | |
| Sanofi Pasteur INC. | $37.38 | 2022-2025 | |
| Madrigal Pharmaceuticals | $34.94 | 2025 | Rezdiffra |
| Phadia US INC. | $31.10 | 2021-2023 | Immunocap |
| Sage Therapeutics, LLC | $29.47 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $26.66 | 2025 | Gemtesa |
| Seqirus USA INC | $25.13 | 2025 | Fluad, Flucelvax |
| Mannkind Corporation | $19.27 | 2025 | |
| Eisai INC. | $18.41 | 2021 | |
| Cranial Technologies, INC | $16.33 | 2024 | Doc Band |
| Biohaven Pharmaceuticals, INC. | $15.61 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.28 | 2022 | |
| Evofem Biosciences, INC. | $8.35 | 2025 | Phexxi, Solosec, Phexx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.